Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

CytoLogix

This article was originally published in The Gray Sheet

Executive Summary

Maker of the Artisan automated cellular diagnostic system secures $26 mil. in private equity financing announced Jan. 24. The round was led by EGS Healthcare Capital Partners and also included Oxford Bioscience Partners and Hambrecht and Quist. Funding brings total investment in CytoLogix to over $40 mil., firm says. Proceeds will go toward new product development, manufacturing, international expansion and alliance efforts. Separately, CytoLogix announces the initiation of patent infringement proceedings against Ventana Medical Systems, the same day the U.S. Patent and Trademark Office awarded the firm a key patent related to slide heating technology. Cambridge, Massachusetts-based CytoLogix contends that Ventana's Benchmark and Discovery instruments infringe the patent, and seeks a permanent injunction against those products, as well as damages

You may also be interested in...



CytoLogix v. Ventana: Anti-Trust Allegations Build On Trade Secret Suit

CytoLogix is accusing Ventana Medical Systems with engaging in a four-year pattern of anti-competitive and predatory behavior, including misappropriation of trade secrets and deceptive marketing practices related to slide staining equipment

Surprise As FDA Approves Sarepta’s Duchenne Drug Vyondys 53

UsernamePublicRestriction

Register

MT014434

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel